Pharmacovigilance Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032
CHAPTER 1. Industry Overview of Pharmacovigilance Market
1.1. Definition and Scope
1.1.1. Definition of Pharmacovigilance
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Pharmacovigilance Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Pharmacovigilance Market By Clinical Trial Phase
1.2.3. Pharmacovigilance Market By Service
1.2.4. Pharmacovigilance Market By Type
1.2.5. Pharmacovigilance Market By Therapeutic Area
1.2.6. Pharmacovigilance Market By End-Use
1.2.7. Pharmacovigilance Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Sources
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Pharmacovigilance Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Pharmacovigilance Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2022
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Pharmacovigilance Market By Clinical Trial Phase
4.1. Introduction
4.2. Pharmacovigilance Market Revenue By Clinical Trial Phase
4.2.1. Pharmacovigilance Market Revenue (USD Billion) and Forecast, By Clinical Trial Phase, 2020-2032
4.2.2. Pre-clinical
4.2.2.1. Pre-clinical Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
4.2.3. Phase I
4.2.3.1. Phase I Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
4.2.4. Phase II
4.2.4.1. Phase II Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
4.2.5. Phase III
4.2.5.1. Phase III Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
4.2.6. Phase IV
4.2.6.1. Phase IV Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 5. Pharmacovigilance Market By Service
5.1. Introduction
5.2. Pharmacovigilance Market Revenue By Service
5.2.1. Pharmacovigilance Market Revenue (USD Billion) and Forecast, By Service, 2020-2032
5.2.2. In-house
5.2.2.1. In-house Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.3. Contract Outsourcing
5.2.3.1. Contract Outsourcing Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 6. Pharmacovigilance Market By Type
6.1. Introduction
6.2. Pharmacovigilance Market Revenue By Type
6.2.1. Pharmacovigilance Market Revenue (USD Billion) and Forecast, By Type, 2020-2032
6.2.2. Symptom Checking & Medical Assistance
6.2.2.1. Symptom Checking & Medical Assistance Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.3. Appointment Scheduling and Medical Guidance
6.2.3.1. Appointment Scheduling and Medical Guidance Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.4. Targeted Spontaneous Reporting
6.2.4.1. Targeted Spontaneous Reporting Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.5. Cohort Event Monitoring
6.2.5.1. Cohort Event Monitoring Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.6. EHR Mining
6.2.6.1. EHR Mining Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 7. Pharmacovigilance Market By Therapeutic Area
7.1. Introduction
7.2. Pharmacovigilance Market Revenue By Therapeutic Area
7.2.1. Pharmacovigilance Market Revenue (USD Billion) and Forecast, By Therapeutic Area, 2020-2032
7.2.2. Oncology
7.2.2.1. Oncology Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.3. Neurology
7.2.3.1. Neurology Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.4. Cardiology
7.2.4.1. Cardiology Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.5. Respiratory Systems
7.2.5.1. Respiratory Systems Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.6. Others
7.2.6.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 8. Pharmacovigilance Market By End-Use
8.1. Introduction
8.2. Pharmacovigilance Market Revenue By End-Use
8.2.1. Pharmacovigilance Market Revenue (USD Billion) and Forecast, By End-Use, 2020-2032
8.2.2. Pharmaceuticals
8.2.2.1. Pharmaceuticals Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
8.2.3. Biotechnology Companies
8.2.3.1. Biotechnology Companies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
8.2.4. Medical Device Manufacturers
8.2.4.1. Medical Device Manufacturers Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
8.2.5. Others
8.2.5.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 9. North America Pharmacovigilance Market By Country
9.1. North America Pharmacovigilance Market Overview
9.2. U.S.
9.2.1. U.S. Pharmacovigilance Market Revenue (USD Billion) and Forecast By Clinical Trial Phase, 2020-2032
9.2.2. U.S. Pharmacovigilance Market Revenue (USD Billion) and Forecast By Service, 2020-2032
9.2.3. U.S. Pharmacovigilance Market Revenue (USD Billion) and Forecast By Type, 2020-2032
9.2.4. U.S. Pharmacovigilance Market Revenue (USD Billion) and Forecast By Therapeutic Area, 2020-2032
9.2.5. U.S. Pharmacovigilance Market Revenue (USD Billion) and Forecast By End-Use, 2020-2032
9.3. Canada
9.3.1. Canada Pharmacovigilance Market Revenue (USD Billion) and Forecast By Clinical Trial Phase, 2020-2032
9.3.2. Canada Pharmacovigilance Market Revenue (USD Billion) and Forecast By Service, 2020-2032
9.3.3. Canada Pharmacovigilance Market Revenue (USD Billion) and Forecast By Type, 2020-2032
9.3.4. Canada Pharmacovigilance Market Revenue (USD Billion) and Forecast By Therapeutic Area, 2020-2032
9.3.5. Canada Pharmacovigilance Market Revenue (USD Billion) and Forecast By End-Use, 2020-2032
9.4. North America PEST Analysis
CHAPTER 10. Europe Pharmacovigilance Market By Country
10.1. Europe Pharmacovigilance Market Overview
10.2. U.K.
10.2.1. U.K. Pharmacovigilance Market Revenue (USD Billion) and Forecast By Clinical Trial Phase, 2020-2032
10.2.2. U.K. Pharmacovigilance Market Revenue (USD Billion) and Forecast By Service, 2020-2032
10.2.3. U.K. Pharmacovigilance Market Revenue (USD Billion) and Forecast By Type, 2020-2032
10.2.4. U.K. Pharmacovigilance Market Revenue (USD Billion) and Forecast By Therapeutic Area, 2020-2032
10.2.5. U.K. Pharmacovigilance Market Revenue (USD Billion) and Forecast By End-Use, 2020-2032
10.3. Germany
10.3.1. Germany Pharmacovigilance Market Revenue (USD Billion) and Forecast By Clinical Trial Phase, 2020-2032
10.3.2. Germany Pharmacovigilance Market Revenue (USD Billion) and Forecast By Service, 2020-2032
10.3.3. Germany Pharmacovigilance Market Revenue (USD Billion) and Forecast By Type, 2020-2032
10.3.4. Germany Pharmacovigilance Market Revenue (USD Billion) and Forecast By Therapeutic Area, 2020-2032
10.3.5. Germany Pharmacovigilance Market Revenue (USD Billion) and Forecast By End-Use, 2020-2032
10.4. France
10.4.1. France Pharmacovigilance Market Revenue (USD Billion) and Forecast By Clinical Trial Phase, 2020-2032
10.4.2. France Pharmacovigilance Market Revenue (USD Billion) and Forecast By Service, 2020-2032
10.4.3. France Pharmacovigilance Market Revenue (USD Billion) and Forecast By Type, 2020-2032
10.4.4. France Pharmacovigilance Market Revenue (USD Billion) and Forecast By Therapeutic Area, 2020-2032
10.4.5. France Pharmacovigilance Market Revenue (USD Billion) and Forecast By End-Use, 2020-2032
10.5. Spain
10.5.1. Spain Pharmacovigilance Market Revenue (USD Billion) and Forecast By Clinical Trial Phase, 2020-2032
10.5.2. Spain Pharmacovigilance Market Revenue (USD Billion) and Forecast By Service, 2020-2032
10.5.3. Spain Pharmacovigilance Market Revenue (USD Billion) and Forecast By Type, 2020-2032
10.5.4. Spain Pharmacovigilance Market Revenue (USD Billion) and Forecast By Therapeutic Area, 2020-2032
10.5.5. Spain Pharmacovigilance Market Revenue (USD Billion) and Forecast By End-Use, 2020-2032
10.6. Rest of Europe
10.6.1. Rest of Europe Pharmacovigilance Market Revenue (USD Billion) and Forecast By Clinical Trial Phase, 2020-2032
10.6.2. Rest of Europe Pharmacovigilance Market Revenue (USD Billion) and Forecast By Service, 2020-2032
10.6.3. Rest of Europe Pharmacovigilance Market Revenue (USD Billion) and Forecast By Type, 2020-2032
10.6.4. Rest of Europe Pharmacovigilance Market Revenue (USD Billion) and Forecast By Therapeutic Area, 2020-2032
10.6.5. Rest of Europe Pharmacovigilance Market Revenue (USD Billion) and Forecast By End-Use, 2020-2032
10.7. Europe PEST Analysis
CHAPTER 11. Asia Pacific Pharmacovigilance Market By Country
11.1. Asia Pacific Pharmacovigilance Market Overview
11.2. China
11.2.1. China Pharmacovigilance Market Revenue (USD Billion) and Forecast By Clinical Trial Phase, 2020-2032
11.2.2. China Pharmacovigilance Market Revenue (USD Billion) and Forecast By Service, 2020-2032
11.2.3. China Pharmacovigilance Market Revenue (USD Billion) and Forecast By Type, 2020-2032
11.2.4. China Pharmacovigilance Market Revenue (USD Billion) and Forecast By Therapeutic Area, 2020-2032
11.2.5. China Pharmacovigilance Market Revenue (USD Billion) and Forecast By End-Use, 2020-2032
11.3. Japan
11.3.1. Japan Pharmacovigilance Market Revenue (USD Billion) and Forecast By Clinical Trial Phase, 2020-2032
11.3.2. Japan Pharmacovigilance Market Revenue (USD Billion) and Forecast By Service, 2020-2032
11.3.3. Japan Pharmacovigilance Market Revenue (USD Billion) and Forecast By Type, 2020-2032
11.3.4. Japan Pharmacovigilance Market Revenue (USD Billion) and Forecast By Therapeutic Area, 2020-2032
11.3.5. Japan Pharmacovigilance Market Revenue (USD Billion) and Forecast By End-Use, 2020-2032
11.4. India
11.4.1. India Pharmacovigilance Market Revenue (USD Billion) and Forecast By Clinical Trial Phase, 2020-2032
11.4.2. India Pharmacovigilance Market Revenue (USD Billion) and Forecast By Service, 2020-2032
11.4.3. India Pharmacovigilance Market Revenue (USD Billion) and Forecast By Type, 2020-2032
11.4.4. India Pharmacovigilance Market Revenue (USD Billion) and Forecast By Therapeutic Area, 2020-2032
11.4.5. India Pharmacovigilance Market Revenue (USD Billion) and Forecast By End-Use, 2020-2032
11.5. Australia
11.5.1. Australia Pharmacovigilance Market Revenue (USD Billion) and Forecast By Clinical Trial Phase, 2020-2032
11.5.2. Australia Pharmacovigilance Market Revenue (USD Billion) and Forecast By Service, 2020-2032
11.5.3. Australia Pharmacovigilance Market Revenue (USD Billion) and Forecast By Type, 2020-2032
11.5.4. Australia Pharmacovigilance Market Revenue (USD Billion) and Forecast By Therapeutic Area, 2020-2032
11.5.5. Australia Pharmacovigilance Market Revenue (USD Billion) and Forecast By End-Use, 2020-2032
11.6. South Korea
11.6.1. South Korea Pharmacovigilance Market Revenue (USD Billion) and Forecast By Clinical Trial Phase, 2020-2032
11.6.2. South Korea Pharmacovigilance Market Revenue (USD Billion) and Forecast By Service, 2020-2032
11.6.3. South Korea Pharmacovigilance Market Revenue (USD Billion) and Forecast By Type, 2020-2032
11.6.4. South Korea Pharmacovigilance Market Revenue (USD Billion) and Forecast By Therapeutic Area, 2020-2032
11.6.5. South Korea Pharmacovigilance Market Revenue (USD Billion) and Forecast By End-Use, 2020-2032
11.7. Rest of Asia-Pacific
11.7.1. Rest of Asia-Pacific Pharmacovigilance Market Revenue (USD Billion) and Forecast By Clinical Trial Phase, 2020-2032
11.7.2. Rest of Asia-Pacific Pharmacovigilance Market Revenue (USD Billion) and Forecast By Service, 2020-2032
11.7.3. Rest of Asia-Pacific Pharmacovigilance Market Revenue (USD Billion) and Forecast By Type, 2020-2032
11.7.4. Rest of Asia-Pacific Pharmacovigilance Market Revenue (USD Billion) and Forecast By Therapeutic Area, 2020-2032
11.7.5. Rest of Asia-Pacific Pharmacovigilance Market Revenue (USD Billion) and Forecast By End-Use, 2020-2032
11.8. Asia Pacific PEST Analysis
CHAPTER 12. Latin America Pharmacovigilance Market By Country
12.1. Latin America Pharmacovigilance Market Overview
12.2. Brazil
12.2.1. Brazil Pharmacovigilance Market Revenue (USD Billion) and Forecast By Clinical Trial Phase, 2020-2032
12.2.2. Brazil Pharmacovigilance Market Revenue (USD Billion) and Forecast By Service, 2020-2032
12.2.3. Brazil Pharmacovigilance Market Revenue (USD Billion) and Forecast By Type, 2020-2032
12.2.4. Brazil Pharmacovigilance Market Revenue (USD Billion) and Forecast By Therapeutic Area, 2020-2032
12.2.5. Brazil Pharmacovigilance Market Revenue (USD Billion) and Forecast By End-Use, 2020-2032
12.3. Mexico
12.3.1. Mexico Pharmacovigilance Market Revenue (USD Billion) and Forecast By Clinical Trial Phase, 2020-2032
12.3.2. Mexico Pharmacovigilance Market Revenue (USD Billion) and Forecast By Service, 2020-2032
12.3.3. Mexico Pharmacovigilance Market Revenue (USD Billion) and Forecast By Type, 2020-2032
12.3.4. Mexico Pharmacovigilance Market Revenue (USD Billion) and Forecast By Therapeutic Area, 2020-2032
12.3.5. Mexico Pharmacovigilance Market Revenue (USD Billion) and Forecast By End-Use, 2020-2032
12.4. Rest of Latin America
12.4.1. Rest of Latin America Pharmacovigilance Market Revenue (USD Billion) and Forecast By Clinical Trial Phase, 2020-2032
12.4.2. Rest of Latin America Pharmacovigilance Market Revenue (USD Billion) and Forecast By Service, 2020-2032
12.4.3. Rest of Latin America Pharmacovigilance Market Revenue (USD Billion) and Forecast By Type, 2020-2032
12.4.4. Rest of Latin America Pharmacovigilance Market Revenue (USD Billion) and Forecast By Therapeutic Area, 2020-2032
12.4.5. Rest of Latin America Pharmacovigilance Market Revenue (USD Billion) and Forecast By End-Use, 2020-2032
12.5. Latin America PEST Analysis
CHAPTER 13. Middle East & Africa Pharmacovigilance Market By Country
13.1. Middle East & Africa Pharmacovigilance Market Overview
13.2. GCC
13.2.1. GCC Pharmacovigilance Market Revenue (USD Billion) and Forecast By Clinical Trial Phase, 2020-2032
13.2.2. GCC Pharmacovigilance Market Revenue (USD Billion) and Forecast By Service, 2020-2032
13.2.3. GCC Pharmacovigilance Market Revenue (USD Billion) and Forecast By Type, 2020-2032
13.2.4. GCC Pharmacovigilance Market Revenue (USD Billion) and Forecast By Therapeutic Area, 2020-2032
13.2.5. GCC Pharmacovigilance Market Revenue (USD Billion) and Forecast By End-Use, 2020-2032
13.3. South Africa
13.3.1. South Africa Pharmacovigilance Market Revenue (USD Billion) and Forecast By Clinical Trial Phase, 2020-2032
13.3.2. South Africa Pharmacovigilance Market Revenue (USD Billion) and Forecast By Service, 2020-2032
13.3.3. South Africa Pharmacovigilance Market Revenue (USD Billion) and Forecast By Type, 2020-2032
13.3.4. South Africa Pharmacovigilance Market Revenue (USD Billion) and Forecast By Therapeutic Area, 2020-2032
13.3.5. South Africa Pharmacovigilance Market Revenue (USD Billion) and Forecast By End-Use, 2020-2032
13.4. Rest of Middle East & Africa
13.4.1. Rest of Middle East & Africa Pharmacovigilance Market Revenue (USD Billion) and Forecast By Clinical Trial Phase, 2020-2032
13.4.2. Rest of Middle East & Africa Pharmacovigilance Market Revenue (USD Billion) and Forecast By Service, 2020-2032
13.4.3. Rest of Middle East & Africa Pharmacovigilance Market Revenue (USD Billion) and Forecast By Type, 2020-2032
13.4.4. Rest of Middle East & Africa Pharmacovigilance Market Revenue (USD Billion) and Forecast By Therapeutic Area, 2020-2032
13.4.5. Rest of Middle East & Africa Pharmacovigilance Market Revenue (USD Billion) and Forecast By End-Use, 2020-2032
13.5. Middle East & Africa PEST Analysis
CHAPTER 14. Player Analysis Of Pharmacovigilance Market
14.1. Pharmacovigilance Market Company Share Analysis
14.2. Competition Matrix
14.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
14.2.2. New Product Launches and Product Enhancements
14.2.3. Mergers And Acquisition In Global Pharmacovigilance Market
14.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 15. Company Profile
15.1. ArisGlobal
15.1.1. Company Snapshot
15.1.2. Business Overview
15.1.3. Financial Overview
15.1.3.1. Revenue (USD Billion), 2022
15.1.3.2. ArisGlobal 2022 Pharmacovigilance Business Regional Distribution
15.1.4. Product /Service and Specification
15.1.5. Recent Developments & Business Strategy
15.2. BioClinica Inc.
15.3. Capgemini
15.4. Cognizant
15.5. ICON plc.
15.6. IQVIA
15.7. Laboratory Corporation of America Holdings
15.8. Parexel International Corp.
15.9. TAKE Solutions Ltd.
15.10. United BioSource LLC
15.11. Wipro Ltd.
15.12. ClinQuest Group B.V. (Linical Americas)
Frequently Asked Questions
What was the size of the global pharmacovigilance market in 2022?
The size of pharmacovigilance market was USD 7.9 billion in 2022.
What is the pharmacovigilance market CAGR from 2023 to 2032?
The pharmacovigilance market CAGR during the analysis period of 2023 to 2032 is 11.2%.
Which are the key players in the pharmacovigilance market?
The key players operating in the global pharmacovigilance market are ArisGlobal, BioClinica Inc., Capgemini, Cognizant, ICON plc., IQVIA, Laboratory Corporation of America Holdings, Parexel International Corp., TAKE Solutions Ltd., United BioSource LLC, Wipro Ltd., and ClinQuest Group B.V. (Linical Americas).
Which region dominated the global pharmacovigilance market share?
North America region held the dominating position in pharmacovigilance industry during the analysis period of 2023 to 2032.
Which region registered fastest CAGR from 2023 to 2032?
Asia-Pacific region exhibited fastest growing CAGR for market of pharmacovigilance during the analysis period of 2023 to 2032.
What are the current trends in the global pharmacovigilance industry?
The current trends and dynamics in the pharmacovigilance industry include increasing global pharmaceutical and biotechnology R&D activities, growing awareness of drug safety and regulatory compliance, and rising incidence of adverse drug reactions (ADRs).
Which material held the maximum share in 2022?
The phase IV held the maximum share of the pharmacovigilance industry.?
Select Licence Type
Connect with our sales team
Why Acumen Research And Consulting
100%
Customer Satisfaction
24x7
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
